-Bloomberg
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals’ (NASDAQ:NRXP) Zyesami (aviptadil). The Company is developing aviptadil in collaboration…